James Bown, MD
Gastroenterology · St George, UTNPI 1629081260
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 256 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 36.2% of the total.
Across 256 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$505
- Takeda Pharmaceuticals U.S.A., Inc.$416
- Sanofi$279
- Pfizer$172
- Bristol Myers Squibb$138
- plus $1K from 23 others
What the payments were for
- Food & beverage$4,32398%
- Education$842%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 98 | $1,593 |
| Johnson & Johnson | 29 | $505 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $416 |
| Sanofi | 13 | $279 |
| Pfizer | 10 | $172 |
| Bristol Myers Squibb | 8 | $138 |
| Boston Scientific | 5 | $133 |
| QOL Medical, LLC | 8 | $129 |
| Nestle Healthcare Nutrition Inc. | 7 | $122 |
| Intercept Pharmaceuticals, Inc. | 7 | $113 |
| Madrigal Pharmaceuticals | 5 | $105 |
| Merck | 5 | $85 |
| Gilead | 5 | $77 |
| Regeneron Healthcare Solutions, Inc. | 3 | $69 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $60 |
| Lucid Diagnostics Inc. | 3 | $54 |
| Daiichi Sankyo Inc. | 3 | $46 |
| Organon | 2 | $42 |
| Shire North American Group Inc | 2 | $35 |
| Ironwood Pharmaceuticals, Inc | 2 | $35 |
| Braintree Laboratories, Inc. | 2 | $35 |
| Phathom Pharmaceuticals, Inc. | 2 | $33 |
| Orphalan Inc | 1 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Ardelyx, Inc. | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| UCB, Inc. | 1 | $17 |
| Alfasigma USA, Inc. | 1 | $15 |
| Amgen | 1 | $13 |
How this compares
$4,407 in reported general payments places this provider in the 65th percentile of 122 gastroenterology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 450 | $4,321 |
| Budesonide DrBudesonide | 12 | $1,873 |
| Omeprazole | 149 | $1,342 |
| Colestipol Hcl | 18 | $1,003 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 12 | $842 |
| Famotidine | 89 | $570 |
| Sucralfate | 13 | $358 |
| Clarithromycin | 11 | $349 |
| Fluconazole | 16 | $235 |
| Amoxicillin | 13 | $108 |
| Sulfasalazine | 12 | $107 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in St George
- John Erikson YapSt George$94K
- George JeungSt George$5K
- Brien MillerSt George$5K
- Phillip ObergSt George$4K
- Christoph WoerleinSt George$2K
- Scott DiamondSt George$2K
- Terry BoxSalt Lake City$302K
- Richard GilroySalt Lake City$192K
- Kyle EliasonOgden$128K
- Umaprasanna KarnamRiverton$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.